Pediatric Cancer Studies Triggered by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) Aim at Labels, Not at Improved Treatment

被引：0

作者：

Rose, K. ^{[1
]}

机构：

[1] Klausrose Consulting, Med Sci, CH-4125 Riehen, Switzerland

来源：

PEDIATRIC BLOOD & CANCER | 2019年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V409 SIOP1

引用

页码：S361 / S362

页数：2

共 50 条

[31] Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations
Marina Ghadanian
Ellen Schafheutle
Therapeutic Innovation & Regulatory Science, 2024, 58 : 79 - 113
[32] Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
Wiedermann C.J.
Eisendle K.
Journal of Pharmaceutical Policy and Practice, 10 (1)
[33] Analysis of the Gene Therapies Authorized by the United States Food and Drug Administration and the European Medicines Agency
Ghanem, Buthainah
Seoane-Vazquez, Enrique
Brown, Lawrence
Rodriguez-Monguio, Rosa
MEDICAL CARE, 2023, 61 (07) : 438 - 447
[34] Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study
Boyle, Jemma M.
Hegarty, Gemma
Frampton, Christopher
Harvey-Jones, Elizabeth
Dodkins, Joanna
Beyer, Katharina
George, Gincy
Sullivan, Richard
Booth, Christopher
Aggarwal, Ajay
EUROPEAN JOURNAL OF CANCER, 2021, 155 : 136 - 144
[35] Preclinical efficacy in therapeutic area guidelines from the US Food and Drug Administration and the European Medicines Agency: a cross-sectional study
Langhof, Holger
Chin, William Wei Lim
Wieschowski, Susanne
Federico, Carole
Kimmelman, Jonathan
Strech, Daniel
BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (22) : 4229 - 4238
[36] Evolution and current status of United States Food and Drug Administration and European Medicines Agency regulatory guidance for studies of nosocomial pneumonia
Talbot, George H.
CURRENT OPINION IN CRITICAL CARE, 2018, 24 (05) : 379 - 384
[37] Cystic Fibrosis Treatment: A Paradigm for New Pediatric Medicines, Globalization of Drug Development and the Role of the European Medicines Agency
Rose, Klaus
Spigarelli, Michael G.
CHILDREN-BASEL, 2015, 2 (01): : 108 - 130
[38] New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis
Lexchin, Joel
PLOS ONE, 2023, 18 (06):
[39] Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
Doua, Joachim Y.
Van Geertruyden, Jean-Pierre
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2014, 19 (01) : 23 - 36
[40] The role of clinical outcome assessment (COA) data in the drug approval process of medicines for the treatment of restless legs syndrome (RLS): a review of the labels of medicines approved by the FDA and the EMA
Emery, M. -P.
Anfray, C.
Perrier, L. -L.
Acquadro, C.
MOVEMENT DISORDERS, 2017, 32

← 1 2 3 4 5 →